Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for REGN

Stock Name	Regeneron Pharmaceuticals Inc
Ticker	REGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75886F1075
LEI	549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria: (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL: Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors: Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN: In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC: Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.: Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.: D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) REGN holdings

Date	Number of REGN Shares Held	Base Market Value of REGN Shares	Local Market Value of REGN Shares	Change in REGN Shares Held	Change in REGN Base Value	Current Price per REGN Share Held	Previous Price per REGN Share Held
2025-11-11 (Tuesday)	66,958	USD 45,166,519	USD 45,166,519
2025-11-10 (Monday)	66,958	USD 43,840,081	USD 43,840,081	171	USD -74,375	USD 654.74	USD 657.53
2025-11-07 (Friday)	66,787	USD 43,914,456	USD 43,914,456	0	USD 711,949	USD 657.53	USD 646.87
2025-11-06 (Thursday)	66,787	USD 43,202,507	USD 43,202,507	171	USD 289,146	USD 646.87	USD 644.19
2025-11-05 (Wednesday)	66,616	USD 42,913,361	USD 42,913,361	0	USD 1,078,513	USD 644.19	USD 628
2025-11-04 (Tuesday)	66,616	USD 41,834,848	USD 41,834,848	172	USD -838,811	USD 628	USD 642.25
2025-11-03 (Monday)	66,444	USD 42,673,659	USD 42,673,659	0	USD -634,540	USD 642.25	USD 651.8
2025-10-31 (Friday)	66,444	USD 43,308,199	USD 43,308,199	0	USD -148,835	USD 651.8	USD 654.04
2025-10-30 (Thursday)	66,444	USD 43,457,034	USD 43,457,034	860	USD 636,585	USD 654.04	USD 652.91
2025-10-29 (Wednesday)	65,584	USD 42,820,449	USD 42,820,449	494	USD 220,346	USD 652.91	USD 654.48
2025-10-28 (Tuesday)	65,090	USD 42,600,103	USD 42,600,103	0	USD 4,502,275	USD 654.48	USD 585.31
2025-10-27 (Monday)	65,090	USD 38,097,828	USD 38,097,828	0	USD 479,062	USD 585.31	USD 577.95

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BDZVHG35

Show aggregate share trades of REGN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 171 665.990 653.190 654.470 USD 111,914 641.91
2025-11-06 BUY 171 657.000 641.260 642.834 USD 109,925 641.81
2025-11-04 BUY 172 646.221 625.140 627.248 USD 107,887 641.87
2025-10-30 BUY 860 664.000 645.000 646.900 USD 556,334 641.74
2025-10-29 BUY 494 652.910 659.980 659.273 USD 325,681 641.68
2025-10-22 SELL -684 584.740 588.710 588.313 USD -402,406 642.98 Profit of 37,390 on sale
2025-10-20 BUY 342 576.770 582.650 582.062 USD 199,065 643.72
2025-10-17 BUY 855 578.050 579.040 578.941 USD 494,995 644.09
2025-10-15 BUY 1,368 576.420 584.870 584.025 USD 798,946 644.48
2025-10-03 BUY 1,190 600.000 618.010 616.209 USD 733,289 645.16
2025-10-02 BUY 170 600.000 605.410 604.869 USD 102,828 645.42
2025-09-30 BUY 340 562.270 574.040 572.863 USD 194,773 646.18
2025-09-26 BUY 340 563.900 564.610 564.539 USD 191,943 647.19
2025-09-25 BUY 340 555.510 579.000 576.651 USD 196,061 647.74
2025-09-18 BUY 181 598.710 600.000 599.871 USD 108,577 648.03
2025-09-17 BUY 546 585.500 587.670 587.453 USD 320,749 648.42
2025-09-11 SELL -182 568.200 570.760 570.504 USD -103,832 650.40 Profit of 14,541 on sale
2025-09-10 BUY 364 555.830 560.000 559.583 USD 203,688 651.00
2025-07-17 SELL -364 550.000 554.480 554.032 USD -201,668 653.64 Profit of 36,257 on sale
2025-07-16 BUY 613 547.930 558.350 557.308 USD 341,630 654.32
2025-07-11 SELL -1,440 567.740 568.460 568.388 USD -818,479 656.16 Profit of 126,387 on sale
2025-07-02 BUY 9,900 547.740 551.500 551.124 USD 5,456,128 659.00
2025-06-25 BUY 360 520.290 525.630 525.096 USD 189,035 662.83
2025-06-20 BUY 333 509.720 521.310 520.151 USD 173,210 666.01
2025-06-13 BUY 95 529.240 529.550 529.519 USD 50,304 671.50
2025-06-11 BUY 356 518.600 528.370 527.393 USD 187,752 673.78
2025-06-10 BUY 356 523.530 529.990 529.344 USD 188,446 674.92
2025-06-04 SELL -178 484.930 499.900 498.403 USD -88,716 680.55 Profit of 32,422 on sale
2025-04-23 BUY 178 587.850 603.770 602.178 USD 107,188 712.12
2025-04-10 SELL -1,424 546.390 571.990 569.430 USD -810,868 727.37 Profit of 224,907 on sale
2025-04-08 SELL -178 556.810 586.030 583.108 USD -103,793 731.06 Profit of 26,336 on sale
2025-04-07 SELL -178 572.780 591.540 589.664 USD -104,960 732.90 Profit of 25,497 on sale
2025-04-04 SELL -890 573.450 612.990 609.036 USD -542,042 734.78 Profit of 111,911 on sale
2025-04-01 BUY 1,534 617.000 641.240 638.816 USD 979,944 737.51
2025-03-31 SELL -528 634.230 640.720 640.071 USD -337,957 738.77 Profit of 52,115 on sale
2025-03-21 BUY 1,950 658.480 661.000 660.748 USD 1,288,459 746.22
2025-03-14 SELL -2,704 666.870 686.980 684.969 USD -1,852,156 751.65 Profit of 180,307 on sale
2025-03-07 SELL -338 707.510 729.750 727.526 USD -245,904 754.95 Profit of 9,269 on sale
2025-03-04 SELL -169 675.490 697.460 695.263 USD -117,499 758.18 Profit of 10,633 on sale
2025-02-25 BUY 338 723.470 739.000 737.447 USD 249,257 762.91
2025-02-19 SELL -169 685.660 688.670 688.369 USD -116,334 767.66 Profit of 13,400 on sale
2025-02-13 BUY 507 674.270 677.690 677.348 USD 343,415 775.04
2025-02-12 BUY 169 663.860 670.980 670.268 USD 113,275 777.31
2025-02-11 BUY 676 665.460 680.790 679.257 USD 459,178 779.64
2025-01-02 BUY 82 715.190 726.810 725.648 USD 59,503 815.28
2024-12-30 BUY 14,577 702.590 708.970 708.332 USD 10,325,355 818.70
2024-11-18 SELL -1,800 762.000 762.700 762.630 USD -1,372,734 883.97 Profit of 218,410 on sale
2024-11-08 SELL -120 828.420 830.730 830.499 USD -99,660 892.43 Profit of 7,432 on sale
2024-10-30 BUY 63 922.790 935.860 934.553 USD 58,877 941.44
2024-10-21 SELL -119 968.500 991.240 988.966 USD -117,687 0.00 Loss of -117,687 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	171	665.990	653.190	654.470	USD 111,914	641.91
2025-11-06	BUY	171	657.000	641.260	642.834	USD 109,925	641.81
2025-11-04	BUY	172	646.221	625.140	627.248	USD 107,887	641.87
2025-10-30	BUY	860	664.000	645.000	646.900	USD 556,334	641.74
2025-10-29	BUY	494	652.910	659.980	659.273	USD 325,681	641.68
2025-10-22	SELL	-684	584.740	588.710	588.313	USD -402,406	642.98 Profit of 37,390 on sale
2025-10-20	BUY	342	576.770	582.650	582.062	USD 199,065	643.72
2025-10-17	BUY	855	578.050	579.040	578.941	USD 494,995	644.09
2025-10-15	BUY	1,368	576.420	584.870	584.025	USD 798,946	644.48
2025-10-03	BUY	1,190	600.000	618.010	616.209	USD 733,289	645.16
2025-10-02	BUY	170	600.000	605.410	604.869	USD 102,828	645.42
2025-09-30	BUY	340	562.270	574.040	572.863	USD 194,773	646.18
2025-09-26	BUY	340	563.900	564.610	564.539	USD 191,943	647.19
2025-09-25	BUY	340	555.510	579.000	576.651	USD 196,061	647.74
2025-09-18	BUY	181	598.710	600.000	599.871	USD 108,577	648.03
2025-09-17	BUY	546	585.500	587.670	587.453	USD 320,749	648.42
2025-09-11	SELL	-182	568.200	570.760	570.504	USD -103,832	650.40 Profit of 14,541 on sale
2025-09-10	BUY	364	555.830	560.000	559.583	USD 203,688	651.00
2025-07-17	SELL	-364	550.000	554.480	554.032	USD -201,668	653.64 Profit of 36,257 on sale
2025-07-16	BUY	613	547.930	558.350	557.308	USD 341,630	654.32
2025-07-11	SELL	-1,440	567.740	568.460	568.388	USD -818,479	656.16 Profit of 126,387 on sale
2025-07-02	BUY	9,900	547.740	551.500	551.124	USD 5,456,128	659.00
2025-06-25	BUY	360	520.290	525.630	525.096	USD 189,035	662.83
2025-06-20	BUY	333	509.720	521.310	520.151	USD 173,210	666.01
2025-06-13	BUY	95	529.240	529.550	529.519	USD 50,304	671.50
2025-06-11	BUY	356	518.600	528.370	527.393	USD 187,752	673.78
2025-06-10	BUY	356	523.530	529.990	529.344	USD 188,446	674.92
2025-06-04	SELL	-178	484.930	499.900	498.403	USD -88,716	680.55 Profit of 32,422 on sale
2025-04-23	BUY	178	587.850	603.770	602.178	USD 107,188	712.12
2025-04-10	SELL	-1,424	546.390	571.990	569.430	USD -810,868	727.37 Profit of 224,907 on sale
2025-04-08	SELL	-178	556.810	586.030	583.108	USD -103,793	731.06 Profit of 26,336 on sale
2025-04-07	SELL	-178	572.780	591.540	589.664	USD -104,960	732.90 Profit of 25,497 on sale
2025-04-04	SELL	-890	573.450	612.990	609.036	USD -542,042	734.78 Profit of 111,911 on sale
2025-04-01	BUY	1,534	617.000	641.240	638.816	USD 979,944	737.51
2025-03-31	SELL	-528	634.230	640.720	640.071	USD -337,957	738.77 Profit of 52,115 on sale
2025-03-21	BUY	1,950	658.480	661.000	660.748	USD 1,288,459	746.22
2025-03-14	SELL	-2,704	666.870	686.980	684.969	USD -1,852,156	751.65 Profit of 180,307 on sale
2025-03-07	SELL	-338	707.510	729.750	727.526	USD -245,904	754.95 Profit of 9,269 on sale
2025-03-04	SELL	-169	675.490	697.460	695.263	USD -117,499	758.18 Profit of 10,633 on sale
2025-02-25	BUY	338	723.470	739.000	737.447	USD 249,257	762.91
2025-02-19	SELL	-169	685.660	688.670	688.369	USD -116,334	767.66 Profit of 13,400 on sale
2025-02-13	BUY	507	674.270	677.690	677.348	USD 343,415	775.04
2025-02-12	BUY	169	663.860	670.980	670.268	USD 113,275	777.31
2025-02-11	BUY	676	665.460	680.790	679.257	USD 459,178	779.64
2025-01-02	BUY	82	715.190	726.810	725.648	USD 59,503	815.28
2024-12-30	BUY	14,577	702.590	708.970	708.332	USD 10,325,355	818.70
2024-11-18	SELL	-1,800	762.000	762.700	762.630	USD -1,372,734	883.97 Profit of 218,410 on sale
2024-11-08	SELL	-120	828.420	830.730	830.499	USD -99,660	892.43 Profit of 7,432 on sale
2024-10-30	BUY	63	922.790	935.860	934.553	USD 58,877	941.44
2024-10-21	SELL	-119	968.500	991.240	988.966	USD -117,687	0.00 Loss of -117,687 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	208,659	1,635	312,812	66.7%
2025-09-18	236,485	3,679	387,519	61.0%
2025-09-17	229,191	716	370,895	61.8%
2025-09-16	173,632	584	271,020	64.1%
2025-09-15	204,491	251	334,496	61.1%
2025-09-12	117,504	33	222,760	52.7%
2025-09-11	125,478	3,137	286,516	43.8%
2025-09-10	195,068	481	339,885	57.4%
2025-09-09	129,168	994	274,520	47.1%
2025-09-08	250,895	396	527,062	47.6%
2025-09-05	170,149	290	289,566	58.8%
2025-09-04	188,227	2,103	360,619	52.2%
2025-09-03	185,679	344	438,111	42.4%
2025-09-02	191,954	138	476,288	40.3%
2025-08-29	133,226	685	236,726	56.3%
2025-08-28	116,560	2,177	256,675	45.4%
2025-08-27	113,719	465	243,836	46.6%
2025-08-26	210,376	450	400,199	52.6%
2025-08-25	149,130	68	363,377	41.0%
2025-08-22	211,822	3,244	701,770	30.2%
2025-08-21	257,492	3,416	446,439	57.7%
2025-08-20	327,738	572	559,133	58.6%
2025-08-19	118,472	2,191	324,311	36.5%
2025-08-18	146,282	388	277,909	52.6%
2025-08-15	209,923	3,375	441,752	47.5%
2025-08-14	157,569	3,623	429,327	36.7%
2025-08-13	111,342	233	362,786	30.7%
2025-08-12	117,647	171	310,775	37.9%
2025-08-11	129,513	2,676	284,757	45.5%
2025-08-08	128,559	1,038	431,841	29.8%
2025-08-07	166,648	1,560	352,877	47.2%
2025-08-06	176,311	624	397,089	44.4%
2025-08-05	154,257	115	353,744	43.6%
2025-08-04	200,758	1,913	409,897	49.0%
2025-08-01	349,775	3,745	728,720	48.0%
2025-07-31	222,350	476	549,344	40.5%
2025-07-30	106,839	1,689	231,761	46.1%
2025-07-29	149,359	276	292,667	51.0%
2025-07-28	103,687	1,380	245,287	42.3%
2025-07-25	103,783	556	259,069	40.1%
2025-07-24	156,974	2,397	291,677	53.8%
2025-07-23	168,734	1,708	355,372	47.5%
2025-07-22	116,324	617	304,880	38.2%
2025-07-21	98,482	900	250,107	39.4%
2025-07-18	183,174	1,051	391,909	46.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE